<DOC>
	<DOCNO>NCT00748891</DOCNO>
	<brief_summary>This study carry patient advance solid tumour assess two different type image scan best measure activity experimental drug call Cediranib . The study compare image test : Dynamic Contrast Enhanced CT ( DCE-CT ) Dynamic Contrast Enhanced MRI ( DCE-MRI ) . It look scan accurate best predicts response treatment . Cediranib think work stop blood flow cancer , scan assess blood flow . Studying response cancer measure change blood flow may provide useful information guide way manage cancer future .</brief_summary>
	<brief_title>DCE CT/MRI Scanning Study Patients With Solid Tumours ( AstraZeneca Royal Marsden Hospital Imaging Study )</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histologically confirm metastatic tumour refractory standard therapy At least one lesion size â‰¥3cm long diameter suitable repeat assessment DCECT DCEMRI Patients must able undergo DCECT DCEMRI scanning procedure Life expectancy least 12 week Patients hormone refractory prostate cancer ( HRPC ) Patients history poorly control high blood pressure Ineligibility MRI scan DCECT DCEMRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>tumour</keyword>
	<keyword>advanced sell tumour</keyword>
	<keyword>image</keyword>
	<keyword>DCE-CT Scan</keyword>
	<keyword>DCE-MRI scan</keyword>
	<keyword>Cediranib</keyword>
	<keyword>Recentin</keyword>
</DOC>